Danica Pension Livsforsikringsaktieselskab acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 92,429 shares of the medical research company's stock, valued at approximately $46,340,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Legacy Wealth Managment LLC ID boosted its stake in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after purchasing an additional 22 shares during the last quarter. Allied Private Wealth LLC bought a new position in Thermo Fisher Scientific during the second quarter worth $26,000. High Note Wealth LLC lifted its holdings in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at $28,000. Finally, JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $28,000. Institutional investors own 89.23% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on TMO shares. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. KeyCorp reaffirmed an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Piper Sandler boosted their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a research report on Monday, July 27th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.
Read Our Latest Stock Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Stock Performance
Shares of Thermo Fisher Scientific stock opened at $614.32 on Thursday. The firm has a market capitalization of $227.14 billion, a P/E ratio of 33.05, a price-to-earnings-growth ratio of 2.40 and a beta of 0.85. The business's fifty day simple moving average is $536.26 and its 200 day simple moving average is $508.51. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter last year, the company posted $4.28 earnings per share. The firm's quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.
Insider Activity
In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at $71,191,194.75. This trade represents a 7.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 52,053 shares of company stock valued at $30,643,589. 0.33% of the stock is currently owned by corporate insiders.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
